Availability of Affordable Generic Medicines

1. At a Glance

• Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) is the flagship Government of India campaign to provide quality generic medicines at 50–80% lower MRP than branded equivalents via dedicated retail outlets called Janaushadhi Kendras (JAKs/PMBJKs) [S1][S2].
• Implementing agency: Pharmaceuticals & Medical Devices Bureau of India (PMBI) (earlier BPPI) under Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers [S1][S2].
• Relevant for UPSC: intersection of health (SDG-3), out-of-pocket expenditure, IPR/patents, National List of Essential Medicines (NLEM), price control (NPPA/DPCO).

2. Why in the News

• PIB release (20 Mar 2026): 18,646 JAKs operational across the country as on 28.02.2026; 727 in Maharashtra, 634 in Madhya Pradesh [S1].
• Product basket expanded from 1,654 → 2,425 items in 5 years; current basket = 2,110 medicines + 315 surgicals/consumables/devices [S1][S2].
• Government targets 20,000 Kendras and 2,200 medicines + 320 surgicals by 31.03.2026 [S2].
• Janaushadhi Saptah 2026 culminated in 8th Janaushadhi Diwas on 7 March 2026 [S2].

3. Background & Evolution

• Originally launched as Jan Aushadhi Campaign in 2008 by Dept. of Pharmaceuticals; relaunched and rebranded as PMBJP in 2015–16 [S2].
• Earlier implementing body: Bureau of Pharma PSUs of India (BPPI), since renamed Pharmaceuticals & Medical Devices Bureau of India (PMBI) [S2].
• Milestone: cumulative Janaushadhi sales MRP ₹7,700 crore by June 2025, citizen savings ≈ ₹38,000 crore vs branded equivalents [S2].

4. Core Static Facts

• Scheme name: Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) [S1].
• Nodal Ministry: Ministry of Chemicals & Fertilizers — Department of Pharmaceuticals [S1].
• Implementing agency: PMBI (formerly BPPI) [S2].
• Kendras opened (as on 28.02.2026): 18,646; target 20,000 by 31.03.2026 [S1][S2].
• Product basket: 2,110 medicines + 315 surgicals/consumables/devices; target 2,200 + 320 by 31.03.2026 [S1][S2].
• Therapeutic coverage: cardiovascular, anti-cancer, anti-diabetic, anti-infectives, anti-allergic, gastro-intestinal, nutraceuticals — 29 therapeutic categories [S1][S2].
• Price differential: 50–80% cheaper than branded; MRP capped at max 50% of average of top 3 branded equivalents (PMBJP policy) [S1].
• Footfall: ~10–12 lakh persons/day across Kendras [S2].
• Basket aligns with National List of Essential Medicines (NLEM) (except lab reagents & vaccines) [S1].

5. Multi-Dimensional Analysis

Economic / Health-financing - India's out-of-pocket expenditure (OOPE) is dominated by medicines; cumulative citizen savings via PMBJP ≈ ₹38,000 crore address catastrophic health expenditure [S2]. - Promotes domestic generic industry; complements price control under DPCO 2013 / NPPA ecosystem.

Social / Equity - Wider rural penetration via Kendras run by PACS (Primary Agricultural Credit Societies) and individual entrepreneurs, including SC/ST/women [S2]. - Reduces healthcare access gap between branded and generic markets — critical for BPL, elderly, chronic-disease patients [S1].

Administrative - Federal coordination: states allot space (govt. hospitals, PHCs); Centre supplies via PMBI's distribution network [S2]. - Bottlenecks: stock-outs, quality perception, doctor prescription behaviour favouring brands.

Scientific / Quality assurance - All Janaushadhi medicines tested at NABL-accredited / WHO-GMP certified labs; sourced from WHO-GMP compliant suppliers [S2].

Legal / Constitutional - Linked to Article 21 (Right to Health) jurisprudence; Drugs & Cosmetics Act, 1940; Patents Act, 1970 (Section 3(d) — anti-evergreening) enables generic manufacture.

6. Recent Developments (last 12–18 months)

• 20 Mar 2026: PIB confirms 18,646 JAKs; basket of 2,110+315 items [S1].
• Mar 2026: Expansion target announced — 20,000 Kendras, 2,200 medicines, 320 surgicals by 31.03.2026 [S2].
• 7 Mar 2026: 8th Janaushadhi Diwas; theme reinforcing affordable quality generics [S2].
• Jun 2025: Cumulative MRP sales crossed ₹7,700 crore; estimated savings ₹38,000 crore [S2].
• Continued onboarding of PACS as Kendra operators under Ministry of Cooperation convergence [S2].

7. Prelims Hooks

• PMBJP is administered by Department of Pharmaceuticals, not Ministry of Health & Family Welfare [S1].
• Implementing agency: PMBI (rebranded from BPPI) [S2].
• Scheme originally launched in 2008; relaunched as PMBJP in 2015–16 [S2].
• JAK count as on 28.02.2026 = 18,646 [S1].
• Maharashtra leads major states with 727 Kendras; Madhya Pradesh has 634 [S1].
• Product basket: 2,110 medicines + 315 surgicals/devices (2026) [S1].
• Janaushadhi medicines priced 50–80% below branded equivalents [S1].
• Basket aligned with NLEM, excluding lab reagents and vaccines [S1].
• 8th Janaushadhi Diwas observed on 7 March 2026 [S2].
• Cumulative savings to citizens ≈ ₹38,000 crore (by Jun 2025) [S2].
• Daily footfall ~10–12 lakh persons [S2].
• Target: 20,000 Kendras by 31 March 2026 [S2].

8. Mains Relevance

• GS-II: Government policies & interventions for development (Health) — Issues relating to development & management of Social Sector — Health.
• GS-III: Indian Economy — Pharmaceutical sector; Inclusive growth.
• Plausible question stems: 1. "Affordable access to medicines is central to realising the Right to Health. Critically examine the role of PMBJP in reducing out-of-pocket health expenditure in India." 2. "Discuss the structural challenges in scaling up the Janaushadhi network and suggest reforms to ensure quality and trust in generic medicines." 3. "Examine the linkages between India's patent regime, generic pharmaceutical industry, and public health objectives."

9. Related Topics to Study Next

• National List of Essential Medicines (NLEM) 2022 — basis for PMBJP basket.
• Drug Price Control Order (DPCO) 2013 & NPPA — statutory price regulation.
• Patents Act 1970 / Section 3(d) — enables Indian generics.
• Ayushman Bharat – PM-JAY — complementary financial protection.
• Production-Linked Incentive (PLI) for Pharma & Bulk Drugs — supply-side ecosystem.
• National Health Policy 2017 — affordability and access goals.
• Out-of-pocket expenditure (NHA Estimates) — macro context.
• WHO–TRIPS flexibilities — global IPR/health debate.

10. Common Errors / Trap Areas

• Wrong ministry: PMBJP sits under Chemicals & Fertilizers (Pharma Dept.), NOT Ministry of Health & Family Welfare.
• Implementing body confusion: Current body is PMBI, not BPPI (renamed).
• NLEM vs PMBJP basket: PMBJP basket includes nearly all NLEM medicines except lab reagents and vaccines — students often miss this exclusion [S1].
• Confusing with AMRIT outlets (under MoHFW, for cancer/cardiac drugs at AIIMS-type hospitals) — different scheme.
• Launch year: Scheme initiated 2008, re-launched as PMBJP in 2015 — both years frequently misquoted.

11. Sources

• [S1] Availability of Affordable Generic Medicines, PIB, Dept. of Pharmaceuticals (20 Mar 2026) — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2242915 — (tier: 1)
• [S2] Expansion of PMBJKs to Reduce Healthcare Costs / PMBJP Journey, PIB — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2242928 ; https://www.pib.gov.in/PressReleseDetailm.aspx?PRID=2236292 ; https://www.pib.gov.in/PressReleaseIframePage.aspx?PRID=2067441 — (tier: 1)